ClinicalTrials.gg
TerminatedNCT01865084Updated Oct 9, 2019Results posted

A Study of Tadalafil for Duchenne Muscular Dystrophy

A Phase 3 interventional study of Tadalafil and Placebo in Muscular Dystrophy, Duchenne, sponsored by Eli Lilly and Company. Terminated at 62 sites in 16 countries. Open to male participants aged 7 Years to 14 Years. Per ClinicalTrials.gov, last updated 2019-10-09.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Why this study was terminated
The study is being terminated for lack of efficacy

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
331
Allocation
Randomized
Ages
7 Years to 14 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 233 studies in Muscular Dystrophy, Duchenne with a site in United States — 35 open to participants now, 61 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.

Enrollment
3rd of 172
331 · median 25
Started
2013
with 12 others
Phase 3
32 of 233
3 open now
Registered
60th of 233
by date

Among the 233 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 3rd largest by enrollment of the 172 interventional ones that give a count, is one of 13 that started in 2013, is one of 32 in phase 3, and was the 60th registered.

Muscular Dystrophy, Duchenne

481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 106 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

35 of the 233 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.

This study: 7 Years to 14 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 233 studies in Muscular Dystrophy, Duchenne with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this study is to determine if tadalafil can slow the decline in walking ability of boys who have Duchenne muscular dystrophy (DMD). The study will also assess the safety of tadalafil and any side effects that might be associated with it in boys who have DMD. Participants will receive study treatment (tadalafil or placebo) for the first 48 weeks of the study, and can then continue into an open label extension (OLE) that consists of two periods during which all participants will receive tadalafil. In OLE period 1, all participants will receive tadalafil for 48 weeks. Participants completing OLE period 1 will continue into OLE period 2 and will receive tadalafil for at least another 48 weeks.

03

Conditions studied

  • Muscular Dystrophy, Duchenne
04

Who can participate

Ages eligible
7 Years to 14 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ambulant males with Duchenne muscular dystrophy (DMD) confirmed by typical clinical presentation (onset of clinical signs or symptoms before 6 years of age supported by an elevated serum creatinine kinase level, and ongoing difficulty with walking) together with either a record of a genetic confirmation of the DMD diagnosis, or a record of muscle showing near-complete dystrophin deficiency (excluding revertant fibers)
  • Receiving systemic for a minimum of 6 months immediately prior to screening, with no significant change in total daily dosage or dosing regimen (except those adjusting for weight changes) for a minimum of 3 months immediately prior to screening and a reasonable expectation that total daily dosage and dosing regimen will not change significantly (except for adjustments for weight) for the duration of the study
  • Able to complete the six minute walk distance (6MWD) test with results within 20% of each other at a minimum of 2 pre-randomization assessments
  • (LVEF) ≥50% as determined by echocardiogram
  • Written from parents/legal guardian will be obtained prior to any study procedure being performed. In addition, the child may be required to give documented assent, if capable.

Exclusion criteria

Exclusion Criteria:

  • Symptomatic cardiomyopathy or heart failure
  • Change in prophylactic treatment for heart failure within 3 months prior to start of study treatment
  • Cardiac rhythm disorder
  • History of participation in gene or cell-based therapy , or antisense oligonucleotide or stop codon read-through therapy
  • Unable to take orally administered tablets
  • Use of any pharmacologic treatment, other than , that might have an effect on muscle strength within 3 months prior to the start of study treatment (for example, growth hormone, anabolic steroids including testosterone)
  • New or changed treatment with herbal or dietary supplements being taken with an expectation of an effect on muscle strength or function during 1 month prior to first dose of study drug
  • Surgery that might have an effect on muscle strength or function within 3 months before study entry or planned surgery at any time during the study
  • Evidence of a lower limb injury that may affect performance on the 6MWD
  • Severe behavioral problems, including severe autism or attention deficit disorders, that may interfere with completion of the 6MWD
  • Any to tadalafil (use of any form of organic nitrate, either regularly and/or intermittently, or known serious to tadalafil)
  • History of significant renal insufficiency or clinical evidence of cirrhosis
  • Have known allergy to any of the in tadalafil tablets, notably lactose
  • Current Phosphodiesterase Type 5 (PDE5) inhibitor therapy or treatment within the past 6 months
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
331 participants (actual)

Study arms

  • Experimental
    Placebo

    Placebo taken orally once daily.

    Drug: Placebo

  • Experimental
    0.3 mg/kg Tadalafil

    0.3 milligram per kilogram (mg/kg) tadalafil taken orally once daily.

    Drug: Tadalafil

  • Experimental
    0.6 mg/kg Tadalafil

    0.6 mg/kg tadalafil taken orally once daily.

    Drug: Tadalafil

Interventions

  • Administered orally

    Also known as: LY450190, Cialis

  • DrugPlacebo

    Also known as: Administered orally

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Six Minute Walk Distance (6MWD) in Meters

    6MWD measured the distance in meters a participant was able to walk in 6 minutes. The study used 6MWD procedure modified specifically for use in boys with Duchenne muscular dystrophy (DMD), including standardized verbal encouragement at specific intervals to maintain attention to the test, and use of a "safety chaser" to walk behind the participant during testing (McDonald et al., 2010a). The LS mean (LSM) change from baseline, standard error was derived using mixed model repeated measures (MMRM) methodology with factors for pooled country, treatment, visit, treatment-by-visit interaction and baseline 6MWD as a covariate.

    Time frame: Baseline, Week 48

Secondary outcomes

  1. Change From Baseline in the North Star Ambulatory Assessment (NSAA) Global Score

    The NSAA is a functional scale specifically designed for ambulant boys with DMD that can provide additional information on motor functions important in maintaining normal ambulation and other activities important to everyday life. The NSAA is a 17-item evaluation of standing, ability to transition from lying to sitting, sitting to standing, and other mobility assessments. Each of the 17 items is evaluated on an ordinal scale of 0, 1, or 2, with higher scores reflecting better performance on the assessment, for a total maximum score of 34. This score was transformed to a 0 to 100 scale for the key analysis (referred to as linearized), with higher transformed scores reflecting better performance.The LS mean (LSM) change from baseline standard error was derived using mixed model repeated measures methodology (MMRM) with factors for pooled country, treatment, visit, treatment-by-visit interaction and Day 1 value as baseline covariate.

    Time frame: Baseline, Week 48

  2. Change From Baseline in Timed Function Tests in Seconds

    Timed function tests included time it took to rise from floor, walk 10 meters, ascend 4 stairs, and descend 4 stairs.The lower the time in seconds taken, the better the performance. The LS mean change from baseline, standard error, was derived using mixed model repeated measures methodology (MMRM) with factors for pooled country, treatment, visit, treatment-by-visit interaction and Day 1 value as baseline covariate.

    Time frame: Baseline, Week 48

  3. Time to Persistent 10% Worsening in 6MWD

    Time on study until the 6MWD becomes 10% less than the baseline 6MWD and continues at that level or lower until the end of study.

    Time frame: Baseline through Week 48

  4. Time to Persistent 10% Worsening in Timed Function Tests (TFT)

    Time on study until the TFT becomes 10% worse than the baseline TFT and continues at that level or lower until the end of study. The time to persistent 10% worsening is the observed time after baseline until the first observed timepoint where their time used for the TFTs is \>110% of the baseline time and all the time values observed afterward are also \>110% of baseline. If the participant discontinues prior to experiencing persistent worsening, this outcome for the participant is censored at the date of discontinuation of the double-blind period. Only participants with complete evaluable data were analyzed. Complete evaluable data was defined as having baseline measurement, complete dates at evaluable visits and a post-baseline measurement at each evaluable visit.

    Time frame: Baseline through Week 48

  5. Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Scores

    PODCI includes a Global Functioning Scale and 5 core scales:Upper Extremity and Physical Function,Transfer/Basic Mobility, Sports/Physical Functioning, Pain/Comfort,and Happiness.The Global Functioning Scale is the mean of the mean scores from 4 of the 5 core scales (all except the happiness core scale).The following PODCI scores were prespecified in the protocol for analysis: Global Functioning, Upper Extremity and Physical Function,Transfer/Basic Mobility, and Sports/Physical Functioning. The Global Functioning Scale and each of the core scales were standardized so that a score of "0" represents a poor outcome/worse health, while "100" is the best possible outcome/best health (i.e., complete range of each score is 0 to 100, with higher scores representing better functioning). The LS mean (LSM) change from baseline,standard error was derived using MMRM with factors for pooled country, treatment, visit, treatment-by-visit interaction and baseline PODC scale as covariate.

    Time frame: Baseline, Week 48

  6. Pharmacokinetics (PK): Apparent Clearance (CL/F) of Tadalafil

    The data reported are population estimate and inter-patient variability.

    Time frame: Weeks 4, 12, 24 and 36: -1 Hour up to 24 Hours Postdose

07

Results

Posted Mar 1, 2017
Limitations and caveats
The Sponsor concluded that the efficacy results do not provide sufficient justification for continuance of the open-label extension (OLE) period of the study, where all participants were receiving daily treatment with tadalafil.

Participant flow

Double Blind Period (DB)
Participant flow — Double Blind Period (DB)
MilestonePlacebo0.3 mg/kg Tadalafil0.6 mg/kg Tadalafil
Started116102113
Received at least one dose of study drug116102112
Completed11198107
Not completed546
Withdrew: Adverse event221
Withdrew: Protocol violation001
Withdrew: Withdrawal by parent/guardian224
Withdrew: Withdrawal by subject100
Open Label Extension (OLE) Period
Participant flow — Open Label Extension (OLE) Period
MilestonePlacebo0.3 mg/kg Tadalafil0.6 mg/kg Tadalafil
Started0150165
Completed0139158
Not completed0117
Withdrew: Adverse event001
Withdrew: Lack of efficacy002
Withdrew: Lost to follow-up010
Withdrew: Withdrawal by parent/guardian082
Withdrew: Withdrawal by subject022

Outcome measures

PrimaryChange From Baseline in Six Minute Walk Distance (6MWD) in Meters

6MWD measured the distance in meters a participant was able to walk in 6 minutes. The study used 6MWD procedure modified specifically for use in boys with Duchenne muscular dystrophy (DMD), including standardized verbal encouragement at specific intervals to maintain attention to the test, and use of a "safety chaser" to walk behind the participant during testing (McDonald et al., 2010a). The LS mean (LSM) change from baseline, standard error was derived using mixed model repeated measures (MMRM) methodology with factors for pooled country, treatment, visit, treatment-by-visit interaction and baseline 6MWD as a covariate.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · Meters
Change From Baseline in Six Minute Walk Distance (6MWD) in Meters
MetersPlacebo0.3 mg/kg Tadalafil0.6 mg/kg Tadalafil
Change From Baseline in Six Minute Walk Distance (6MWD) in Meters-50.99 ± 9.316-64.71 ± 9.809-59.08 ± 9.397
Statistical analysis
  • Placebo vs 0.3 mg/kg Tadalafil · Mixed Models Analysis · p = 0.307 (The p-value is based on the treatment difference LS Mean changes from baseline between tadalafil and placebo.)
  • Placebo vs 0.6 mg/kg Tadalafil · Mixed Models Analysis · p = 0.538 (The p-value is based on the treatment difference LS Mean changes from baseline between tadalafil and placebo.)
SecondaryChange From Baseline in the North Star Ambulatory Assessment (NSAA) Global Score

The NSAA is a functional scale specifically designed for ambulant boys with DMD that can provide additional information on motor functions important in maintaining normal ambulation and other activities important to everyday life. The NSAA is a 17-item evaluation of standing, ability to transition from lying to sitting, sitting to standing, and other mobility assessments. Each of the 17 items is evaluated on an ordinal scale of 0, 1, or 2, with higher scores reflecting better performance on the assessment, for a total maximum score of 34. This score was transformed to a 0 to 100 scale for the key analysis (referred to as linearized), with higher transformed scores reflecting better performance.The LS mean (LSM) change from baseline standard error was derived using mixed model repeated measures methodology (MMRM) with factors for pooled country, treatment, visit, treatment-by-visit interaction and Day 1 value as baseline covariate.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the North Star Ambulatory Assessment (NSAA) Global Score
Units on a scalePlacebo0.3 mg/kg Tadalafil0.6 mg/kg Tadalafil
Change From Baseline in the North Star Ambulatory Assessment (NSAA) Global Score-8.80 ± 1.104-9.31 ± 1.181-8.96 ± 1.115
SecondaryChange From Baseline in Timed Function Tests in Seconds

Timed function tests included time it took to rise from floor, walk 10 meters, ascend 4 stairs, and descend 4 stairs.The lower the time in seconds taken, the better the performance. The LS mean change from baseline, standard error, was derived using mixed model repeated measures methodology (MMRM) with factors for pooled country, treatment, visit, treatment-by-visit interaction and Day 1 value as baseline covariate.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · Seconds
Change From Baseline in Timed Function Tests in Seconds
SecondsPlacebo0.3 mg/kg Tadalafil0.6 mg/kg Tadalafil
Rise from the Floor(n=92,75,89)4.16 ± 1.1203.60 ± 1.2234.81 ± 1.156
10 Meter Walk/Run(n=105,90,100)1.11 ± 0.2040.95 ± 0.2261.12 ± 0.217
Stair Climb (n=116,96,110)3.96 ± 1.0414.10 ± 1.1545.82 ± 1.072
Stair Descend(n=115,95,110)3.19 ± 0.8272.07 ± 0.9153.27 ± 0.853
SecondaryTime to Persistent 10% Worsening in 6MWD

Time on study until the 6MWD becomes 10% less than the baseline 6MWD and continues at that level or lower until the end of study.

Time frame:
Baseline through Week 48
Reported as:
Median · Days
Time to Persistent 10% Worsening in 6MWD
DaysPlacebo0.3 mg/kg Tadalafil0.6 mg/kg Tadalafil
Time to Persistent 10% Worsening in 6MWDNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryTime to Persistent 10% Worsening in Timed Function Tests (TFT)

Time on study until the TFT becomes 10% worse than the baseline TFT and continues at that level or lower until the end of study. The time to persistent 10% worsening is the observed time after baseline until the first observed timepoint where their time used for the TFTs is \>110% of the baseline time and all the time values observed afterward are also \>110% of baseline. If the participant discontinues prior to experiencing persistent worsening, this outcome for the participant is censored at the date of discontinuation of the double-blind period. Only participants with complete evaluable data were analyzed. Complete evaluable data was defined as having baseline measurement, complete dates at evaluable visits and a post-baseline measurement at each evaluable visit.

Time frame:
Baseline through Week 48
Reported as:
Median · Days
Time to Persistent 10% Worsening in Timed Function Tests (TFT)
DaysPlacebo0.3 mg/kg Tadalafil0.6 mg/kg Tadalafil
Rise from the Floor (n=81,67,77)253.0 (170.0 to NA)NA (NA to NA)NA (NA to NA)
Stair Climb (n=112,91,107)255.0 (252.0 to NA)259.0 (176.0 to NA)253.0 (185.0 to NA)
10 Meter Walk/Run (n=98,83,91)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Stair Descend (n=110,91,108)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryChange From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Scores

PODCI includes a Global Functioning Scale and 5 core scales:Upper Extremity and Physical Function,Transfer/Basic Mobility, Sports/Physical Functioning, Pain/Comfort,and Happiness.The Global Functioning Scale is the mean of the mean scores from 4 of the 5 core scales (all except the happiness core scale).The following PODCI scores were prespecified in the protocol for analysis: Global Functioning, Upper Extremity and Physical Function,Transfer/Basic Mobility, and Sports/Physical Functioning. The Global Functioning Scale and each of the core scales were standardized so that a score of "0" represents a poor outcome/worse health, while "100" is the best possible outcome/best health (i.e., complete range of each score is 0 to 100, with higher scores representing better functioning). The LS mean (LSM) change from baseline,standard error was derived using MMRM with factors for pooled country, treatment, visit, treatment-by-visit interaction and baseline PODC scale as covariate.

Time frame:
Baseline, Week 48
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Scores
Units on a scalePlacebo0.3 mg/kg Tadalafil0.6 mg/kg Tadalafil
Global Functioning Scale (n=41,34,34)-8.81 ± 1.770-7.36 ± 1.929-7.34 ± 1.888
Upper Extremity & Physical Function-5.47 ± 1.901-3.73 ± 2.060-2.47 ± 2.042
Transfer/Basic Mobility Core Scale-14.26 ± 3.037-12.50 ± 3.260-12.78 ± 3.279
Sports/Physical Functioning Core Scale-12.47 ± 2.362-11.98 ± 2.552-7.88 ± 2.537
SecondaryPharmacokinetics (PK): Apparent Clearance (CL/F) of Tadalafil

The data reported are population estimate and inter-patient variability.

Time frame:
Weeks 4, 12, 24 and 36: -1 Hour up to 24 Hours Postdose
Reported as:
Geometric mean · Liter per hour (L/hr)
Pharmacokinetics (PK): Apparent Clearance (CL/F) of Tadalafil
Liter per hour (L/hr)0.3 mg/kg Tadalafil and 0.6 mg/kg Tadalafil
Pharmacokinetics (PK): Apparent Clearance (CL/F) of Tadalafil1.79 ± 29.6

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo - DB—5/116 (4.3%)83/116 (71.6%)
0.3 mg/kg Tadalafil -DB—4/102 (3.9%)82/102 (80.4%)
0.6 mg/kg Tadalafil - DB—6/112 (5.4%)92/112 (82.1%)
0.3 mg/kg Tadalafil - OLE—6/150 (4%)68/150 (45.3%)
0.6 mg/kg Tadalafil - OLE—9/165 (5.5%)84/165 (50.9%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventPlacebo - DB0.3 mg/kg Tadalafil -DB0.6 mg/kg Tadalafil - DB0.3 mg/kg Tadalafil - OLE0.6 mg/kg Tadalafil - OLE
FallInjury, poisoning and procedural complications1/1160/1022/1121/1501/165
Femur fractureInjury, poisoning and procedural complications0/1160/1022/1121/1501/165
MyocarditisCardiac disorders0/1161/1020/1120/1500/165
Gastrointestinal infectionInfections and infestations0/1161/1020/1120/1500/165
PneumoniaInfections and infestations0/1161/1020/1120/1501/165
Muscle contractureMusculoskeletal and connective tissue disorders0/1161/1020/1120/1500/165
PharyngotonsillitisInfections and infestations0/1160/1021/1120/1500/165
Pneumonia adenoviralInfections and infestations0/1160/1021/1120/1500/165
VaricellaInfections and infestations0/1160/1021/1120/1500/165
Tendinous contractureMusculoskeletal and connective tissue disorders1/1160/1021/1121/1500/165
Most frequent other events
Showing 10 of 23
Most frequent other events
EventPlacebo - DB0.3 mg/kg Tadalafil -DB0.6 mg/kg Tadalafil - DB0.3 mg/kg Tadalafil - OLE0.6 mg/kg Tadalafil - OLE
HeadacheNervous system disorders36/11640/10243/1128/15014/165
FallInjury, poisoning and procedural complications24/11618/10222/11216/15015/165
NasopharyngitisInfections and infestations16/1168/10218/1128/15012/165
VomitingGastrointestinal disorders14/1166/10217/1129/15010/165
Erection increasedReproductive system and breast disorders3/11610/10217/1122/1504/165
AbasiaGeneral disorders6/11614/1029/11212/15016/165
Spontaneous penile erectionReproductive system and breast disorders4/11613/10213/1123/1504/165
PyrexiaGeneral disorders4/11611/1029/1127/1506/165
Back painMusculoskeletal and connective tissue disorders9/11611/1027/1127/1509/165
Upper respiratory tract infectionInfections and infestations10/11610/10212/1126/1508/165

Baseline characteristics

All participants who were randomized to study drug.

Age, Continuous
Age, Continuous(years)Placebo0.3 mg/kg Tadalafil0.6 mg/kg TadalafilTotal
Mean9.4 ± 1.769.9 ± 2.269.5 ± 1.719.6 ± 1.92
Sex: Female, Male
Sex: Female, Male(Participants)Placebo0.3 mg/kg Tadalafil0.6 mg/kg TadalafilTotal
Female0000
Male116102113331
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo0.3 mg/kg Tadalafil0.6 mg/kg TadalafilTotal
American Indian or Alaska Native0022
Asian15162051
Native Hawaiian or Other Pacific Islander3137
Black or African American0011
White968284262
More than one race2327
Unknown or Not Reported0011
Region of Enrollment
Region of Enrollment(Participants)Placebo0.3 mg/kg Tadalafil0.6 mg/kg TadalafilTotal
Argentina74617
Russian Federation44412
United States393434107
Japan65617
Spain971228
Canada87823
Netherlands2136
Turkey57820
Belgium85417
Taiwan64818
Korea, Republic of34512
Italy88824
France3227
Germany810523
08

Study locations

62 sites
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • University of California, Davis - Health Systems
    Sacramento, California 95817, United States
  • Children's Hospital
    Aurora, Colorado 80045, United States
  • University of Florida Health Science Center
    Gainesville, Florida 32610, United States
  • NW Florida Clinical Research Group
    Gulf Breeze, Florida 32561, United States
  • Nemours Children's Hospital
    Orlando, Florida 32827, United States
  • Ann and Robert Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Washington University Medical Center
    Saint Louis, Missouri 63110, United States
  • Carolinas Healthcare System
    Charlotte, North Carolina 28203, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • Childrens Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Pennsylvania State University College of Medicine
    Hershey, Pennsylvania 17033, United States
  • Childrens Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Childrens Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Children's Medical Center Dallas
    Dallas, Texas 75207, United States
  • Univ of Texas Health Science Center at San Antonio
    San Antonio, Texas 78229, United States
  • University of Utah School of Medicine
    Salt Lake City, Utah 84132, United States
  • Children of the King's Daughters
    Norfolk, Virginia 23510, United States
  • Seattle Children's Hospital Research Foundation
    Seattle, Washington 98105, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Caba, C1204AAD, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gent, 9000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leuven, 3000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Liège, 4000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Calgary, Alberta T3B 6A8, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vancouver, British Columbia V6H 3V4, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Winnipeg, Manitoba R3A 1R9, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Halifax, Nova Scotia B3K 6R8, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    London, Ontario N6C 2V5, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ottawa, Ontario K1H 8L1, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Angers, 49933, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nantes, 44093, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dresden, 01307, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Essen, 45122, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Freiburg, 79106, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Göttingen, 37075, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Munich, 80337, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Genova, 16147, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Milano, 20122, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Padova, 35128, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rome, 00165, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aichi, 467-8602, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nagano, 390-8621, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saitama, 349-0196, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, 187-8551, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 110-744, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leiden, 2300 RC, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nijmegen, 6500 HB, Netherlands
  • University of Puerto Rico, Medical Sciences Campus
    San Juan, 000935, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Moscow, 125412, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 08025, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28046, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Sebastian, 20014, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Valencia, 46026, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kaohsiung, 807, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taipei, 100, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Adana, 01330, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ankara, 06100, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oxford, Oxfordshire OX3 9DU, United Kingdom
09

References and documents

Publications

  • McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Elfring GL, Atkinson L, Reha A, Hirawat S, Miller LL. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve. 2010 Apr;41(4):500-10. doi: 10.1002/mus.21544. PubMed 19941337 ↗
  • Victor RG, Sweeney HL, Finkel R, McDonald CM, Byrne B, Eagle M, Goemans N, Vandenborne K, Dubrovsky AL, Topaloglu H, Miceli MC, Furlong P, Landry J, Elashoff R, Cox D; Tadalafil DMD Study Group. A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy. Neurology. 2017 Oct 24;89(17):1811-1820. doi: 10.1212/WNL.0000000000004570. Epub 2017 Sep 29. PubMed 28972192 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Dec 2015 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2013
First posted
May 30, 2013
Start
Sep 2013
Primary completionActual
Dec 2015
CompletionActual
Mar 2016
Results first posted
Mar 1, 2017
Last update
Oct 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01865084
Responsible party
Sponsor
First posted
May 30, 2013
Start date
Sep 2013
Primary completion
Dec 2015
Completion
Mar 2016
Results posted
Mar 1, 2017
Last update
Oct 9, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion